RU-505 – 1 mg

Brand:
Cayman
CAS:
1314206-29-5
Storage:
-20
UN-No:
Non-Hazardous - /

RU-505 is an inhibitor of the interaction between amyloid-β (Aβ) and fibrinogen, with a higher efficacy for inhibiting monomeric forms of Aβ bound to fibrinogen over oligomeric forms.{26633} In vitro, RU-505 (20 µM) normalizes fibrin clot formation that is disrupted when fibrinogen is bound to Aβ42. RU-505 (35 mg/kg) decreases the incidence of vessel occlusion in the Tg6799 transgenic mouse model of Alzheimer’s disease. Chronic treatment with RU-505 (35 mg/kg, s.c., every other day for 3 months) decreases Aβ deposition in blood vessels and cortical fibrinogen infiltration and microgliosis in the brain of Tg6799 mice. In addition, it improves spatial memory in chronically treated Tg6799 mice compared with vehicle control mice.  

 

Out of stock

SKU: - Category:

Description

An inhibitor of the Aβ and fibrinogen interaction; has a higher efficacy for the monomer form of Aβ bound to fibrinogen over the oligomer form; normalizes fibrin clot formation disrupted by the Aβ42-fibrinogen interaction (20 µM); decreases the incidence of vessel occlusion in Tg6799 mice, a model of Alzheimer’s disease (35 mg/kg); decreases Aβ deposition in blood vessels and cortical fibrinogen infiltration and microgliosis in the brain of Tg6799 mice while improving spatial memory in chronically treated (35 mg/kg, s.c., every other day for 3 months) Tg6799 mice


Formal name: N-[2-(dimethylamino)ethyl]-2-(1,1-dimethylethyl)-7-(4-fluorophenyl)-N-(phenylmethyl)-pyrazolo[1,5-a]pyrimidine-5-carboxamide

Synonyms: 

Molecular weight: 473.6

CAS: 1314206-29-5

Purity: ≥98%

Formulation: A crystalline solid


Product Type|Biochemicals||Research Area|Neuroscience|Behavioral Neuroscience|Learning & Memory||Research Area|Neuroscience|Neurodegenerative Disorders|Alzheimer’s Disease